How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.
about
Anti-TNF agents for paediatric psoriasisInterventions for guttate psoriasisSystemic pharmacological treatments for chronic plaque psoriasisAnti-TNF agents for paediatric psoriasisDefinition of treatment goals for moderate to severe psoriasis: a European consensusIn-vivo imaging of psoriatic lesions with polarization multispectral dermoscopy and multiphoton microscopyClinical nonlinear laser imaging of human skin: a review.The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.Histopathological findings are associated with the clinical types of psoriasis but not with the corresponding lesional psoriasis severity index.Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity.Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians.Disease severity and therapy as predictors of cardiovascular risk in psoriasis: a population-based cohort study.Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire.Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force.Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.Measuring disease activity in psoriatic arthritis.Bioelectrical phase angle and psoriasis: a novel association with psoriasis severity, quality of life and metabolic syndrome.Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis.Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting.Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment.Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis: A Randomized Clinical Trial.Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.Effect of omega-3 fatty acids on disease severity in patients with psoriasis: A systematic review.Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo.Patients' perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey.Development and Validation of a Novel Questionnaire for Adherence with Topical Treatments in Psoriasis (QATOP).Assessing the validity and response distribution of the simplified psoriasis index in patients receiving phototherapy.Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static PhySafety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trialDyslipidemia in Psoriasis: A Case Controlled Study.Viewpoint on handling anti-TNF failure in psoriasis.The diagnosis of early psoriatic arthritis in an outpatient dermatological centre for psoriasis.Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis.Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis.Validation of the Simplified Psoriasis Index in Dutch children and adolescents with plaque psoriasis.The validity, reliability and acceptability of the SAVASI; a new self-assessment score in vitiligo.Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity.
P2860
Q24187673-50141593-0EF6-4E04-91B0-9ACC67998488Q24188296-C8487AE4-DF21-47A6-8CFC-982845E67F38Q24188334-ACD8189D-21B9-49D4-A6F2-F82141953D0AQ24201907-24DC8BF4-FDF5-4975-85C5-F9DF463D0797Q24604445-D3A29D9C-8C14-4734-A4EA-9684EEB2C263Q33915866-330B2796-A2D9-488B-9B1A-DE61641C1C6BQ34177011-464F23D8-23DF-4D5B-87B1-D896A2513516Q34393068-0C09119C-66CD-4BA9-B4F6-CAD7ECA81E14Q35069935-FF60BC2B-3EC2-44AE-93F9-726FE5F686A2Q35155926-3F035083-198E-4CFD-BC34-C15EF8742488Q35175365-D76072E1-B3F2-49F7-BDD6-C0A41C91CE41Q35854188-0A7FAD69-1F0E-4C3C-8516-26559DFCD245Q36063026-89213ADB-1750-489D-B277-AEBE87BA3095Q36175068-36013FA9-858C-4322-93A7-07A9390FF8E9Q36334747-089AA62B-B1F7-4179-BB54-747559921571Q36520126-0E002C17-34B5-437D-A4F3-1D972F39A5BEQ36890664-493FC364-6FEC-43FF-8EFF-04F75A7939D9Q37404210-451A6F81-CB38-487A-8617-4B380639A6E3Q37862369-DD6ABFB6-FA92-451A-99F4-2B75BA25A803Q38030436-83B50B56-C4D7-4CE1-B2A3-577C0A63395BQ38153077-760D4F98-D9A8-4EBF-BF1E-C35A5A44B7FFQ38411982-D2B72B67-440B-48F0-B589-9058C48410C2Q38727735-B63EA405-1402-4D07-99E9-CC2C8421ACE6Q38928071-36876CB1-3768-44E2-804B-76C06B92A297Q39119588-4531B7D8-9A83-446A-80A7-13D83FA2C99BQ39165009-AA9B58E2-6113-40A2-A136-D51C2F764A26Q39189237-05233E9E-DBFB-4950-97AA-2295173D7DD0Q39300408-18F06F37-62E4-4E4C-91DC-9422FFEF6E24Q41008261-073E1D92-D203-43DE-8A1C-C759429C3CC0Q41058601-DC81713C-DA24-4CFA-B8F8-3DBC2AFF11BAQ42119545-69C1F65C-5287-481E-AD12-5E6FC204F80BQ43973219-6AEC284C-0478-47C0-9552-492AF43D189DQ45121095-F515BC83-127F-4AC9-B109-C72EE80DF2B7Q45780381-39694803-8A14-4763-B2DE-F6025452BC01Q46007579-BD8BAE86-AE3F-4C72-935A-859A4A6188CFQ47260366-CEE3EA2F-3023-4BA4-9829-8EBFA02AE14FQ47637078-AEC2836D-B53E-45B1-9125-808435341679Q47647896-38DD9E59-B515-4B28-A81E-0E61691CE145Q48041077-A0447793-5670-4263-8FC6-C202FDF02FBCQ48282794-9ED1B7CD-7F12-4EBC-A10D-A632025BBF89
P2860
How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
How good are clinical severity ...... uation in a systematic review.
@en
How good are clinical severity ...... uation in a systematic review.
@nl
type
label
How good are clinical severity ...... uation in a systematic review.
@en
How good are clinical severity ...... uation in a systematic review.
@nl
prefLabel
How good are clinical severity ...... uation in a systematic review.
@en
How good are clinical severity ...... uation in a systematic review.
@nl
P2093
P356
P1476
How good are clinical severity ...... uation in a systematic review.
@en
P2093
Lidian L A Lecluse
Marie-Louise N F Poulsen
Phyllis I Spuls
Robert S Stern
Tamar Nijsten
P2888
P304
P356
10.1038/JID.2009.391
P407
P577
2009-12-31T00:00:00Z